Syngene International Limited
₹387.25▲ +3.05 (+0.79%)
SYNGENE·NSE·Healthcare
Market Cap
15611.90 Cr
PE Ratio
32.68
Volume
1,12,917
Day High - Low
387.95 - 382.50
52W High-Low
678.95 - 344.45
₹387.25▲ +3.05 (+0.79%)
Market Cap15611.90 Cr
PE Ratio32.68
Volume1,12,917
Day High - Low387.95 - 382.50
52W High-Low678.95 - 344.45
Syngene International Limited (SYNGENE): company summary
The company's annual revenue grew 2.7% to ₹3,739 crore, but net profit fell 36.1% to ₹317 crore.
Syngene International Limited (SYNGENE) is a small-cap Healthcare company valued at ₹15,612 crore operating in Healthcare Research, Analytics & Technology on the NSE and BSE.
- Recent price move
- Syngene International Limited last traded at ₹387.25, modestly up 0.79% on the day.
- Recent developments
- On 2026-06-30, the company reported a net loss of ₹9 crore for the latest quarter, marking a significant swing from the previous year's profit of ₹87 crore. Promoter holding decreased by 0.09 percentage points to 52.59%, while domestic institutional holding increased by 1.58 percentage points to 28.02% and foreign institutional holding fell by 2.08 percentage points to 11.82%.
- Financial performance
- The company's annual revenue grew 2.7% to ₹3,739 crore, but net profit fell 36.1% to ₹317 crore. The latest quarter saw a sharp decline in revenue, down 15.8% year-over-year to ₹736 crore, while net profit swung to a loss of ₹9 crore from a profit of ₹87 crore a year earlier. The net profit margin dropped 5.1 percentage points to 8.5%, and return on equity remained at 0.0%.
- Valuation multiples
- The stock trades at 32.7 times earnings, broadly in line with the Healthcare median of 32.0, 3.20 times book value. It yields 0.3%.
- Things to watch
- The company's latest quarter ended with a net loss of ₹9 crore, a sharp contrast to the previous year's profit of ₹87 crore. The net profit margin has declined by 5.1 percentage points to 8.5%, and return on equity remains at 0.0%. The stock is 46.8% below its 52-week high, reflecting a significant drop from its peak.
- Where it stands
- Syngene International Ltd ended the latest quarter with a net loss of ₹9 crore, contrasting with a profit of ₹87 crore a year earlier. The stock is 46.8% below its 52-week high, and the net profit margin has dropped 5.1 percentage points to 8.5%. The company's return on equity remains at 0.0%.
Summarised by DocStoX's model on 2026-10-03 from company filings, exchange data and news. This is a factual summary, not a rating or a recommendation. Informational only, not investment advice. Consult a SEBI-registered adviser before investing.
DocStoX Score
4.3/10
Weak
Fair Value
Sign in to see
ROE
0.00%
Weak
P/E
32.68x
Fair
Debt / Equity
0.09
Low
Industry
Healthcare
Healthcare Research, Analytics & Technology
Overall View
Mixed
Price performance
NIFTY 500NIFTY SMALLCAP 250
Day₹382.50
₹387.95
52W₹344.45
₹678.95
DocStoX take
Supported by risk (9.4), but held back by momentum (0.0). Risk looks strong at 9.4, but that is offset by momentum at 0.0 and growth at 2.3. We are calling it Mixed rather than resolving the conflict for you.
DocStoX score
Low confidence4.3
/10
Weak
Quality
Modest
ROE 0.0%
Valuation
Rich
P/E 32.7×
Growth
Flat
Revenue +11.3% 5Y CAGR
Risk
Low risk
D/E 0.09
Momentum
Weak
13% of 52-week range
At a glance
Market Cap
₹15,612 Cr
52W High / Low
₹679 / ₹344
Dividend Yield
0.33%
Promoter Holding
52.59%
EPS (TTM)
₹11.85
Book Value
₹120.11
Key highlights
- Low leverage — D/E 0.09
- Profitable in all of the last 5 years
- Profit shrinking 5% a year
- Growth is weak (2.3/10)
2 Positives4 Watchouts
Growth
Financials
Technicals
Peers
News
Forecasts
About the company
More data
Filings, corporate actions and ownership detail — opened on demand.
More Healthcare stocks · Healthcare Research, Analytics & Technology
Explore Syngene International Limited’s valuation
Free deep-dive tools · no sign-up
Fair ValueOur fair-value estimate, upside, and Bear/Base/Bull scenarios.Intrinsic ValueGraham & earnings-power intrinsic value with margin of safety.DCFDiscounted cash flow — free cash flow, growth, value per share.ValuationP/E, P/B, earnings yield and the full multiples picture.Financial RatiosProfitability, leverage and efficiency ratios at a glance.PeersHow it stacks up against its closest listed competitors.
Syngene International Limited peers in Healthcare
Other Healthcare stocks on the NSE & BSE. See the full Healthcare sector list.
Sun Pharmaceutical Industries LimitedDivi's Laboratories LimitedTorrent Pharmaceuticals LimitedApollo Hospitals Enterprise LimitedZydus Lifesciences LimitedLaurus Labs LimitedCipla LimitedDr. Reddy's Laboratories LimitedAurobindo Pharma LimitedMankind Pharma LimitedLupin LimitedManipal Health Enterprises Limited
Compare Syngene International Limited with peers
Syngene International Limited vs Sun Pharmaceutical Industries LimitedSyngene International Limited vs Divi's Laboratories LimitedSyngene International Limited vs Torrent Pharmaceuticals LimitedSyngene International Limited vs Apollo Hospitals Enterprise LimitedSyngene International Limited vs Zydus Lifesciences LimitedSyngene International Limited vs Laurus Labs Limited
Related tools & concepts
Value Syngene International Limited with the ratios and calculators DocStoX uses in its analysis.
P/E RatioPrice to earningsReturn on Equity (ROE)ProfitabilityROCECapital efficiencyDebt to EquityLeverageP/B RatioPrice to bookNet Profit MarginBottom-line efficiencyDCF / Intrinsic ValueEstimate fair valueCAGR CalculatorAnnualised returnDividend YieldIncome on pricePosition SizeRisk-based sizingBrokerage CalculatorCharges on a tradeSIP CalculatorSystematic investing